A Case of IL-7R Deficiency Caused by a Novel Synonymous Mutation and Implications for Mutation Screening in SCID Diagnosis

Fernando Gallego-Bustos, Valer Gotea, José T. Ramos-Amador, Rebeca Rodríguez-Pena, Juana Gil-Herrera, Ana Sastre, Aitor Delmiro, Ghadi Rai, Laura Elintsiki, Luis I. González-Granado and Luis M. Allende

Reported synonymous substitutions are generally non-pathogenic, and rare pathogenic synonymous variants may be disregarded unless there is a high index of suspicion. In a case of IL-7 receptor deficiency severe combined immunodeficiency (SCID), the relevance of a non-reported synonymous variant was only suspected through the use of additional in silico computational tools, which focused on the impact of mutations on gene splicing. The pathogenic nature of the variant was confirmed using experimental validation of the effect on mRNA splicing and IL7 pathway function. This case reinforces the need to use additional experimental methods to establish the functional impact of specific mutations, in particular for cases such as SCID where prompt diagnosis can greatly impact on diagnosis, treatment, and survival.

Keywords: IL-7R, primary immunodeficiency, SCID, splicing, synonymous substitutions

INTRODUCTION

We report a 5-month-old male born to non-consanguineous parents who fulfilled clinical and immunological parameters for severe combined immunodeficiency (SCID). He was admitted with a history of high fever, diarrhea, and oral thrush (Figure 1A). Physical examination revealed failure to thrive and diaphragnocasia. Immunophenotyping showed T-cell lymphopenia and normal to elevated B and NK cells. The lymphoproliferative response was absent, and serum immunoglobulins were very low, leading to the suspicion of T−B+NK+ SCID (Table 1). First, mutations in the IL2RG gene were ruled out, and autosomal recessive IL-7R deficiency was suspected. Sanger sequencing of the IL7R gene revealed a heterozygous non-synonymous mutation (c.353G>A, p.C118Y) in exon 3

Abbreviations: ATG, anti-thymocyte globulin; CADD, combined annotation-dependent depletion; GVHD, graft-versus-host disease; HSC, hematopoietic stem cell transplantation; IL-7R, interleukin 7 receptor; NGS, next-generation sequencing; PBMCs, peripheral blood mononuclear cells; PHA, phytohemagglutinin; SCID, severe combined immunodeficiency; SS, splice site.
**FIGURE 1** | Immune evaluation of patient deficient in IL-7R. (A) Two major aphthous oral ulcers (large ulcers greater than 10 mm in diameter) in a 5-month-old male, involving the posterior veil of soft palate. (B) Lower CD127 expression on CD3 T-cells of IL-7R-deficient patient compared with a healthy donor. (C,D) Significantly lower phosphorylation of STAT5 (phosphoSTAT5, BD biosciences) in response to IL-7 (R&D systems) was observed in T-cells from the patient post-HSCT (IL-7 T cell patient) compared with the healthy donor (IL-7 T cell control). An example of phosphorylation of STAT5 with IL-7 in T-cells from the control (in purple) vs. phosphorylation of STAT5 with IL-7 in T-cells from the patient post-HSCT (in green). Normal phosphoSTAT5 in response to IL-2 (Roche) was observed in the patient (IL-2 T cell patient) and the healthy donor (IL-2 T cell control) \( (n = 2) \). Statistical comparison was performed with unpaired Student’s t-tests, with significance defined as \( *P < 0.01 \); ns: not statistically significant. (E) Impaired IL7R gene expression in CD3 T-cells from IL-7R-deficient patient 1, 2, and 3 years post-HSCT (Pt post-HSCT 1, 2, and 3). These results were compared with P2B (IL-7R-deficient patient with complete immune reconstitution after 19 years post-HSCT) and 10 healthy children donors. GADPH was used as the endogenous gene control. Triplicate data from one experiment are shown.
(Figure 2A). This mutation, inherited from his healthy mother, was previously reported in SCID patients (1). No other missense and nonsense mutations, as well as insertions and deletions, were found in coding exons or exon–intron boundaries in genomic DNA. Since the phenotype of the patient clearly pointed to an IL-7R deficiency due to the absence of CD127 expression and naive CD4 and CD8 T-cells (Table 1; Figure 1B), we reevaluated the coding sequence of the IL7R gene. Apart from the c.353G>A mutation, we only found another heterozygous synonymous mutation that affects codon 111 (c.333T>A, p.V111V) (Genbank NM_002185.3). This mutation was inherited from his healthy father, but its absence from various mutation repositories (dbSNP v.146, Human Gene Mutation Database Professional, ClinVar, 1000 Genomes Project) indicates that it is a rare polymorphism. The CADD tool (http://cadd.gs.washington.edu/score), which was developed to evaluate the deleteriousness of various mutation types, indicated a low potential impact of this mutation (raw score of −0.077; PHRED-like scaled score of 1.906). However, we also evaluated the potential functional impact of this mutation by evaluating its influence on gene splicing with computational tools developed specifically for this purpose (for materials, see Supplementary Material). SplicePort and MaxEntScan indicated that a cryptic donor splice site just upstream of this mutation could be activated, which would result in the truncation of the last 49 nucleotides of exon 3. To verify this prediction, we analyzed the splicing pattern of IL7R mRNA extracted from patient’s PBMCs. In agreement with the expectations, the RT-polymerase chain reaction (PCR) gel revealed the presence of two bands (Figure 2B). Sequencing of RT-PCR products confirmed that the larger fragment contained all correctly spliced exons, whereas the smaller fragment lacked the last 49 nucleotides of exon 3 (Figure 2B). This deletion truncation results in a frameshift that leads to a premature stop codon at residue 119 (c.330del49) and truncation of the protein C-terminus (Figure 2C), indicating loss of functional receptors.

Once the IL-7R deficiency was confirmed, the decision to offer hematopoietic stem cell transplantation (HSCT) was made. The patient received HSCT from an unrelated HLA identical donor at the age of 10 months. The conditioning regimen included ATG, fludarabine, and melphalan. He achieved full donor chimerism 2 months after HSCT (Table S1 in Supplementary Material). The patient is currently 4 years old and although successfully rescued from SCID by HSCT, he has suffered severe complications: hepatic graft-versus-host disease (GvHD), severe malnutrition, and diarrhea caused by norovirus infection, respiratory infections caused by RSV and EBV, steroid-resistant chronic autoimmune thrombocytopenia (Figure 2A). This mutation, inherited from his healthy mother, was previously reported in SCID patients (1). No other missense and nonsense mutations, as well as insertions and deletions, were found in coding exons or exon–intron boundaries in genomic DNA. Since the phenotype of the patient clearly pointed to an IL-7R deficiency due to the absence of CD127 expression and naive CD4 and CD8 T-cells (Table 1; Figure 1B), we reevaluated the coding sequence of the IL7R gene. Apart from the c.353G>A mutation, we only found another heterozygous synonymous mutation that affects codon 111 (c.333T>A, p.V111V) (Genbank NM_002185.3). This mutation was inherited from his healthy father, but its absence from various mutation repositories (dbSNP v.146, Human Gene Mutation Database Professional, ClinVar, 1000 Genomes Project) indicates that it is a rare polymorphism. The CADD tool (http://cadd.gs.washington.edu/score), which was developed to evaluate the deleteriousness of various mutation types, indicated a low potential impact of this mutation (raw score of −0.077; PHRED-like scaled score of 1.906). However, we also evaluated the potential functional impact of this mutation by evaluating its influence on gene splicing with computational tools developed specifically for this purpose (for materials, see Supplementary Material). SplicePort and MaxEntScan indicated that a cryptic donor splice site just upstream of this mutation could be activated, which would result in the truncation of the last 49 nucleotides of exon 3. To verify this prediction, we analyzed the splicing pattern of IL7R mRNA extracted from patient’s PBMCs. In agreement with the expectations, the RT-polymerase chain reaction (PCR) gel revealed the presence of two bands (Figure 2B). Sequencing of RT-PCR products confirmed that the larger fragment contained all correctly spliced exons, whereas the smaller fragment lacked the last 49 nucleotides of exon 3 (Figure 2B). This deletion truncation results in a frameshift that leads to a premature stop codon at residue 119 (c.330del49) and truncation of the protein C-terminus (Figure 2C), indicating loss of functional receptors.

Once the IL-7R deficiency was confirmed, the decision to offer hematopoietic stem cell transplantation (HSCT) was made. The patient received HSCT from an unrelated HLA identical donor at the age of 10 months. The conditioning regimen included ATG, fludarabine, and melphalan. He achieved full donor chimerism 2 months after HSCT (Table S1 in Supplementary Material). The patient is currently 4 years old and although successfully rescued from SCID by HSCT, he has suffered severe complications: hepatic graft-versus-host disease (GvHD), severe malnutrition, and diarrhea caused by norovirus infection, respiratory infections caused by RSV and EBV, steroid-resistant chronic autoimmune

**TABLE 1 | Immunological features of the patient.**

| Parameter | Normal range | Pre-HSCT | 1 year after HSCT | 2 years after HSCT | 3 years after HSCT | P2B |
|-----------|--------------|---------|------------------|------------------|------------------|-----|
| Lymphocyte count (no./μL) and phenotype (%) | | | | | | |
| T cells | | | | | | |
| CD3+ (%) | 52–88 | 6 | 89 | 38 | 59 | 75 |
| CD3*CD27+ (%) | 50–85 | 2 | n.d. | 26 | 13 | 70.6 |
| CD4* (%) | 33–65 | 3 | 23 | 10 | 20 | 39 |
| CD4*CD45RA+CCR7+ (%) | 48–72 | 0 | 0 | 11 | 5.1 | 22.2 |
| CD4*CD45RA+CCR7++ (%) | 22–42 | 99 | 99 | 83 | 94 | 78 |
| CD4*CD45RA+CD31+ (%) | 44–60 | n.d. | n.d. | 7 | 4 | 17.5 |
| CD8* (%) | 17–34 | 2 | 70 | 26 | 36 | 35 |
| CD8*CD45RA+CCR7+ (%) | 26–61 | 0 | 14 | 3.5 | 1.3 | 46.6 |
| CD8*CD45RA+CCR7++ (%) | 2.9–7 | 99 | 84 | 5.7 | 6.4 | 31.6 |
| CD8*CD45RA+CCR7+++ (%) | 19–36 | 55.7 | 85.2 | 20.1 |
| CD8*CD45RA+CCR7+ (%) | 9–34 | n.d. | n.d. | 57.1 | 68.4 | 3 |
| CD8*CD67+ (%) | 1–20 | n.d. | n.d. | 153.6 |
| B cells | | | | | | |
| CD19* (%) | 9–28 | 66 | 0* | 40.7 | 30.7 | 15.3 |
| CD19*CD27+ (%) | 12–35 | n.d. | n.d. | 5.8 | n.d. | 34.8 |
| CD19*CD27+ (naive) (%) | 57–84 | n.d. | n.d. | 90.7 | n.d. | 56.3 |
| CD19*CD27+ (marginal) (%) | 4–12 | n.d. | n.d. | 1.6 | n.d. | 11.1 |
| CD19*CD27+ (switched) (%) | 7–25 | n.d. | n.d. | 4.2 | n.d. | 23.5 |
| CD19*CD7+ (%) | 3.5–12.5 | n.d. | n.d. | 13.1 | n.d. | 2.1 |
| NK cells | | | | | | |
| CD56+CD3– (%) | 2–20 | 23 | 10 | 21.2 | 9.7 | 6.3 |
| Lymphoproliferation (cpm) | | | | | | |
| PHA | >50,000 | 690 | 11,582 | 38,610 | 25,404 | 140,866 |
| Anti-CD3 | >20,000 | 497 | 4587 | 332 | 900 | 48,956 |
| Anti-CD3 + anti-CD28 | >50,000 | 583 | 7589 | 10,348 | 28,770 | 153,308 |
| Serum immunoglobulins | | | | | | |
| IgG (mg/dL) | 400–1100 | 232 | n.d. | 1120 | 649 | 1090 |
| IgA (mg/dL) | 10–160 | <6.67 | n.d. | 312 | 341 | 255 |
| IgM (mg/dL) | 50–180 | 29 | n.d. | 133 | 66 | 61 |
| IgE (IU/L) | 5–165 | n.d. | n.d. | 5 | n.d. | n.d. |

*Rituximab.

n.d., not determined.
FIGURE 2 | Genetic analysis of IL7R gene.

(Continued)
thrombocytopenia (<10,000/mm³) requiring Rituximab, Klebsiella oxytoca, and Enterobacter cloacae sepsis that needed vasoactive drugs and pediatric intensive care unit admission. Immunological reconstitution of the patient was deficient in the T-cell compartment due to reduced recent thymic emigrants, decreased naïve CD4 and CD8 T-cells with a senescent T-cell phenotype, reduced CD127 expression, and impaired proliferation to phytohemagglutinin (PHA) stimulation (Table 1). Analysis of IL-7 induced pSTAT5 (Y694) in T-cells from the patient was also reduced in comparison with healthy donors (Figures 1C,D). At molecular level, IL7R mRNA expression in T-cells in samples post-HSCT was severely reduced in the patient compared with healthy donors (Figure 1E). The immunological findings after HSCT of this patient were compared with another IL-7R deficient patient (P2B) (3) who experienced complete immune reconstitution 19 years post-HSCT (Table 1). The protocols of this study were approved by the Institutional Review Board of Hospital Universitario 12 de Octubre (Madrid, Spain).

METHODS

Flow Cytometry

Proportions and lymphocyte count of T-, B-, and NK-cells were determined in blood samples using conjugated mouse antihuman monoclonal antibodies and analyzed by flow cytometry using a Navios Cytometer (Beckman Coulter, Madrid, Spain).

Proliferation Assay

Heparinized whole blood from the patients were diluted in complete medium and cultured with the following mitogens: PHA (Sigma, Madrid, Spain), anti-CD3 antibody, and anti-CD3 + anti-CD28 antibodies (BDbiosciences, Madrid, Spain). The samples were cultured in triplicate wells for 3 days at 37°C in a humidified incubator containing 5% CO₂, then the wells were pulsed individually with 1 μCi of [³H]-thymidine and incubated during the last 18 h. The amount of radioactivity was measured in a scintillation counter with results expressed as counts per minute.

Immunoglobulins

Total serum immunoglobulins (IgG, IgA, IgM, and IgE) were measured by nephelometry (Beckman Coulter, Madrid, Spain). PCR to amplify the eight exons of IL7R gene, and their flanking regions were carried out using specific primers (Primers available upon request). Purified PCR products were sequenced using an ABI PRISM 3130 genetic analyzer.

Gene Expression

Total RNA was isolated with the RNaseasy plus mini kit (Quiagen, Madrid, Spain). One microgram of total cellular RNA was reverse transcribed using a Transcriptor First Strand cDNA Synthesis Kit (Roche). IL7R gene expression quantification was measured by qRT-PCR using a TaqMan probe in a LightCycler 480 instrument (Roche) according to the manufacturer’s protocol. GADPH was used as the endogenous control, and the level of expression of IL7R was quantitatively measured relative to that in 10 different donors.

BACKGROUND

Severe combined immunodeficiency is a life-threatening disorder characterized by profound impairment of both cellular and humoral immunity. Patients suffer severe and opportunistic infections, protracted diarrhea, and failure to thrive, leading to a fatal outcome in their first year of life (4). SCID is a genetically heterogeneous disorder caused by mutations in more than 20 different genes and is classified according to the immunological phenotype and the corresponding underlying molecular defect. T-B’NK+ SCID phenotype is frequently caused by defects in the α chain of the interleukin-7 receptor (IL-7R or also known as CD127) (5). More than 50 cases of IL-7R deficiency have been described (approximately 10% of SCID cases). A rapid molecular screen is essential to distinguish among SCID patients, so they undergo early HSCT (6).

DISCUSSION

The c.333T>A mutation illustrates the first case of a synonymous nucleotide substitution in the coding region of the IL7R gene that results in abnormal splicing. We note that, as expected for a fourfold degenerate site, the site of this mutation appears to have evolved essentially neutrally in the mammalian lineage as suggested by low, negative phyloP, and GERP+ scores (–0.1606 and –1.61, respectively). However, the phyloP score computed for the primate lineage (0.505) indicates a high level of conservation of this site in primates, which are the only species that have a GT dinucleotide (specific for a donor splice site) preceding it. Therefore, it is tempting to speculate that conservation of this site in primates was maintained to avoid
activation of the cryptic donor splice site in a highly conserved exon (both donor and acceptor consensus dinucleotides are perfectly conserved throughout vertebrates). However, half of all 18 fourfold degenerate sites in exon 3 exhibit similar levels of high conservation in primates, indicating that other mechanisms might be at play concomitantly. This aspect is reinforced by a T>C transition reported at this site (rs199641706) but which is not predicted to activate the preceding cryptic splice site in a manner similar to c.333T>A (Table 2). Nonetheless, it is clear that impact on splicing of this exon can lead to severe phenotypes, as illustrated in this study, which supports splicing as one of the evolutionary forces that maintains the conservation of this site.

Synonymous mutations that affect splicing were known for decades to cause various disease phenotypes (7). In the case of SCID, only two other synonymous mutations were documented, despite the increasing number of diagnosed patients by developing newborn screening programs in Europe and USA (4). Both of those mutations are located in the JAK3 gene: c.1767C>T in exon 13 (8) and c.2961C>T in exon 21 (9). Similarly to the case

### Table 2 | *In silico* analysis of the impact of four synonymous mutations on the strength of neighboring canonical and cryptic donor splice sites using four computational tools.

| Features/scores | c.333T>A | c.1767C>T | c.2961C>T | c.333T>C |
|-----------------|---------|----------|----------|---------|
| Tool            | Gene    | Chromosome | Genomic coordinate (hg19) | Gene strand | Reference transcript | Exon number | Exon size (bps) | Distance from donor SS | Activated cryptic 5' SS |
| SplicePort      | IL7R    | 5         | 35,867,519 | +         | NM_002185 | 3          | 158             | 47                  | 35,867,516 |
| Canonical 3' SS | 0.652896| 0.870339  | 0.721877  | 0.652896 |
| Canonical 5' SS | 1.50677 | 0.446207  | -1.01599  | 1.50677  |
| Cryptic 5' SS   | -0.260474 | NA       | NA       | -0.260474 |
| Mutant canonical 5' SS | 1.03778 | 0.32365 | -1.24002  | 1.56303  |
| Mutant cryptic 5' SS | 0.588026 | 0.634022 | 0.62936   | -0.28607 |
| Δ canonical 5' SS | -0.46899 | -0.12256 | -0.22403  | +0.05626 |
| Δ cryptic 5' SS | +0.84850 | +0.634022 | +0.62936  | -0.02013 |
| Human Splicing Finder | 90.75 | 85.87 | 88.44 | 90.75 |
| Canonical 3' SS | 95.68 | 80.22 | 83.82 | 95.68 |
| Canonical 5' SS | 83.35 | 57.5 | 65.81 | 83.35 |
| Cryptic 5' SS | 95.68 | 80.22 | 83.82 | 95.68 |
| Mutant canonical 5' SS | 88.37 | 84.33 | 92.64 | 83.35 |
| Mutant cryptic 5' SS | 0 | 0 | 0 | 0 |
| Δ canonical 5' SS | +6.02 | +26.83 | +26.83 | 0 |
| Δ cryptic 5' SS | +26.83 | +3.81 | +7.74 | -0.79 |
| MaxEntScan      | 9.26    | 8.5     | 9.26     | 9.26    |
| Canonical 3' SS | 9.14    | 3.45    | 3.44     | 9.14    |
| Canonical 5' SS | 5.64    | -0.78   | -0.34    | 5.64    |
| Cryptic 5' SS | 9.14    | 3.45    | 3.44     | 9.14    |
| Mutant canonical 5' SS | 9.45 | 6.96 | 7.41 | 4.85 |
| Mutant cryptic 5' SS | 0 | 0 | 0 | 0 |
| Δ canonical 5' SS | +3.81 | +7.74 | +7.75 | -0.79 |
| Δ cryptic 5' SS | +7.74 | 0.67 | 0.90 | -0.11 |
| NNSPLICE        | 0.96    | 0.81    | 0.45     | 0.96    |
| Canonical 3' SS | 1.00    | 0.06    | 0.05     | 1.00    |
| Canonical 5' SS | 0.25    | NA      | NA       | 0.25    |
| Cryptic 5' SS | 1.00    | 0.06    | 0.05     | 1.00    |
| Mutant canonical 5' SS | 0.92 | 0.90 | 0.79 | 0.14 |
| Mutant cryptic 5' SS | 0 | 0 | 0 | 0 |
| Δ canonical 5' SS | +0.67 | +0.90 | +0.79 | -0.11 |
| Δ cryptic 5' SS | +0.90 | 0.67 | 0.79 | -0.11 |

(i) The mutation c.333T>C in IL7R is included in this table to illustrate the fact that although it occurs at the same position as the c.333T>A mutation, it is predicted to have an opposite effect on neighboring donor splice sites. Specifically, instead of activating the cryptic donor (5’) splice site, it weakens it, and at the same time, it strengthens the canonical donor splice site of the exon.

(ii) The coordinate of the activated cryptic 5’ (donor) splice site corresponds to the last exonic nucleotide that precedes the GT consensus dinucleotide. Several putative cryptic splice sites were evaluated, but only the one with the highest mutant score is reported here.

Δ canonical 5’ SS in green represents a strengthening of the canonical donor splice site of the exon 3.

Δ canonical 5’ SS in red represents a weakening of the canonical donor splice site of the exon 3.

Δ cryptic 5’ SS in red represents a weakening of a cryptic donor splice site.

Δ cryptic 5’ SS in green represents an activating of a cryptic donor splice site.
of the IL7R mutation investigated here, the deleterious effect of these mutations results from their activating of a cryptic donor splice site. Computational predictions of cryptic splice site activation can be made with tools such as SplicePort and MaxEntScan that can be used for the evaluation of such scenarios (Table 2; Figure S1 in Supplementary Material), although the process is not fully automated. In contrast, tools that predict splicing alteration without specifically evaluating activation of cryptic splice sites have little predicting power for mutations like the ones described herein (Table S2 in Supplementary Material), but they do remain important tools when specific mutations do not activate cryptic splice site. Since effect of mutations cannot be known a priori, it is always recommended that predictions are performed using multiple tools. However, experimental validation of computational predictions needs to be performed whenever you suspect a splicing defect in order to give the appropriate diagnosis.

CONCLUDING REMARK

We report the first case of an IL7R causal synonymous mutation in a male patient with T- B+ NK– SCID phenotype. This mutation (c.333T>G), inherited from his healthy father, activates a cryptic exonic donor splice site that leads to exon truncation (r.330del49) and premature stop codon. It added to a symptomatic missense exonic donor splice site that leads to exon truncation (c.333T>G, p.C118Y) inherited from his healthy mother and together render both IL7R copies non-functional. This case reinforces the need for researchers to functionally evaluate all mutations found in patients. The advent of next-generation sequencing (NGS) provides to researchers with increased genomic coverage, which in turn requires increased efforts for mutation screening. The ever-increasing panel of ever-improving computational tools can facilitate such efforts of functional prioritization, especially in the case of synonymous mutations. Nonetheless, detailed functional reports of specific mutations in patients, such as our report of a causal synonymous mutation in a SCID patient, are ultimately necessary to provide a better understanding of functional impact within the context of specific disease phenotypes.

AUTHOR CONTRIBUTIONS

FG-B performed the laboratory work for this study, computational predictions, and drafted the manuscript. VG performed computational predictions and drafted the manuscript. JR-A, RR-P, JG-H, AS, and LG-G were responsible for the clinical management of the patients. AD, GR, and LE collaborated in computational predictions. LG-G designed the research, collaborated in computational predictions, and drafted the manuscript.

ACKNOWLEDGMENTS

We thank Miguela Menchén, María José Díaz-Madroño and Blas Ali Sánchez-Peral (Roche Diagnostics) for their technical assistance and Xavier Ambroggio for macromolecular modeling of IL7R/IL7 complex.

FUNDING

This research was supported by grants from the Spanish Health Research Fund FIS PI11/1591 and FIS PI16/2053 to LA, PI16/0044 to LG-G and by the Intramural Research Program of the National Human Genome Research Institute (VG and LE). The project has been co-financed with FEDER funds.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at http://journal.frontiersin.org/article/10.3389/fimmu.2016.00443/full#supplementary-material

REFERENCES

1. Giliani S, Mori L, de Saint Basile G, Le Deist F, Rodriguez-Perez C, Forino C, et al. Interleukin-7 receptor alpha (IL-7ralpha) deficiency: cellular and molecular bases. Analysis of clinical, immunological, and molecular features in 16 novel patients. *Immunol Rev* (2005) 203:110–26. doi:10.1111/j.0909-8071.2005.00234.x
2. McElroy CA, Holland PJ, Zhao P, Lim JM, Wells L, Eisenstein E, et al. Structural reorganization of the interleukin-7 signaling complex. *Proc Natl Acad Sci U S A* (2012) 109(7):2503–8. doi:10.1073/pnas.1116852109
3. Bartolomé J, Porta F, Lafranchi A, Rodríguez-Molina JJ, Cela E, Cantalejo A, et al. a cell function after haploidentical in utero bone marrow transplantation in a patient with severe combined immunodeficiency. *Bone Marrow Transplant* (2002) 29(7):625–8. doi:10.1038/sj.bmt.1703410
4. Picard C, Al-Herz W, Bousfiha A, Casanova JL, Chatila T, Conley ME, et al. Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency 2015. *J Clin Immunol* (2015) 35(8):696–726. doi:10.1007/s10875-015-0201-1
5. Puel A, Ziegler SF, Buckley RH, Leonard WJ. Defective IL7R expression ever-improving computational tools can facilitate such efforts of mutation screening. The ever-increasing panel of increased genomic coverage, which in turn requires increased
6. Kwan A, Abraham RS, Currier R, Brower A, Andruszewski K, Abbott JK, et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. *JAMA* (2014) 312(7):729–38. doi:10.1001/jama.2014.9132
7. Candotti F, Oakes SA, Johnston JA, Giliani S, Schumacher RF, Mella P, et al. Structural and functional basis for JAK3-deficient severe combined immunodeficiency. *Blood* (1997) 90(10):3996–4003.
8. Roberts JL, Lengi A, Brown SM, Chen M, Zhou YJ, O'Shea JJ, et al. Janus kinase 3 (JAK3) deficiency: clinical, immunologic, and molecular analyses of 10 patients and outcomes of stem cell transplantation. *Blood* (2004) 103(6):2009–18. doi:10.1182/blood-2003-06-2104

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2016 Gallego-Bustos, Gotea, Ramos-Amador, Rodríguez-Pena, Gil-Herrera, Sastre, Delmoro, Rai, Elbitski, González-Granado and Allende. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.